Drug Profile


Alternative Names: EP 23905; Hexarelin; MF 6003

Latest Information Update: 16 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mediolanum
  • Class Oligopeptides
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Somatotropin deficiency

Most Recent Events

  • 15 May 2007 Examorelin is available for licensing in (http://www.unimi.it)
  • 05 Dec 2002 A preclinical study has been added to the Endocrine Disorders pharmacodynamics section
  • 25 Aug 2002 Europeptides has been acquired from Zentaris AG by Ardana Bioscience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top